FDA Approves New Cholesterol Drug Enlicitide
The once-daily medication offers adults a new way to significantly lower LDL cholesterol levels.
Updated on Oct. 27, 2026 in Heart Disease
Live Poll
Is now a good time to consider switching your cholesterol medication to a newer alternative?
In July 2026, the FDA approved the cholesterol medication enlicitide as a once-daily 20 mg tablet. The drug offers a new option for adults managing cholesterol levels, with clinical trials demonstrating significant LDL reductions.
Why it matters
This approval provides a new treatment pathway for patients needing to lower LDL cholesterol, though its long-term cardiovascular benefits remain under investigation. Clinicians and patients can now consider this PCSK9-blocking therapy as part of a lipid-management strategy.
In two Phase 3 trials involving 2,900 and 303 adults, enlicitide demonstrated a 57% and 59% reduction in LDL cholesterol at 24 weeks compared to placebo. It is currently unknown if these laboratory improvements translate to a reduction in cardiovascular events.
The players
FDA
The United States government agency responsible for protecting public health by regulating pharmaceuticals and medical devices.
The details
Enlicitide functions as a PCSK9 inhibitor, binding to the PCSK9 protein to prevent it from interacting with LDL receptors. By blocking this protein, the medication allows more LDL receptors to remain on the liver surface, increasing the liver's capacity to clear LDL cholesterol from the blood. Reported side effects in the smaller clinical trial included diarrhea in 7% and dizziness in 9% of participants.
Timeline
The FDA approved enlicitide in July 2026.
LDL reduction was measured at 24 weeks in clinical trials.
LDL reduction was sustained for one year in clinical trials.
Health Landscape
The PCSK9 inhibitor class represents a standard biological approach to managing high cholesterol in patients who require intensive lipid lowering. Enlicitide expands this treatment landscape by introducing a new oral option for targeting the PCSK9 protein.
Patients currently managing high cholesterol should discuss whether this new 20 mg daily tablet is an appropriate addition to their treatment plan during their next checkup. It is important to ask a physician about potential side effects like dizziness and how this medication compares to existing lipid-lowering therapies.
The takeaway
Enlicitide is a new FDA-approved treatment that works by blocking the PCSK9 protein to significantly lower LDL cholesterol. Patients interested in this development should track their lipid panels and discuss the potential role of this once-daily medication with their cardiologist.
Further reading
Learn more about managing lipid levels by visiting our Heart Disease section.
Source note: This article includes information reported by Medical Channel Asia.
Live Poll
Is now a good time to consider switching your cholesterol medication to a newer alternative?
